Effect of Colchicine in Patients With Myocardial Infarction
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04218786 |
Recruitment Status :
Enrolling by invitation
First Posted : January 6, 2020
Last Update Posted : November 3, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Over the past years, a substantial volume of evidence has accumulated identifying inflammatory processes as key mediators of the deleterious effects of ischemia/reperfusion-related phenomena in patients presenting with ST-segment-elevation myocardial infarction (STEMI). Nevertheless, equally impressive is the lack of clinically applicable therapeutic strategies that could mitigate these processes, thus providing significant cardioprotection. Despite the well-known fact that inflammation plays an important role in coronary artery disease development and progression, there have been few attempts to systematically examine the potential role of anti-inflammatory treatment in this setting, possibly because of a lack in anti-inflammatory agents without the adverse cardiovascular safety profile of corticosteroids and nonsteroidal anti-inflammatory drugs. Colchicine is a substance with potent anti-inflammatory properties, having a unique mechanism of action, which allows for safe use in patients with cardiovascular disease.
The purpose of the present clinical study is to test the hypothesis that a short course of treatment with colchicine could lead to reduced major adverse cardiovascular events (MACE) in acute MI.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Myocardium; Injury Myocardial Infarction Myocardial Ischemia | Drug: Colchicine Drug: Placebo oral tablet | Phase 2 |
Over the past years, a substantial volume of evidence has accumulated identifying inflammatory processes as key mediators of the deleterious effects of ischemia/reperfusion-related phenomena in patients presenting with ST-segment-elevation myocardial infarction (STEMI). Nevertheless, equally impressive is the lack of clinically applicable therapeutic strategies that could mitigate these processes, thus providing significant cardioprotection.
Despite the well-known fact that inflammation plays an important role in coronary artery disease development and progression, there have been few attempts to systematically examine the potential role of anti-inflammatory treatment in this setting, possibly because of a lack in anti-inflammatory agents without the adverse cardiovascular safety profile of corticosteroids and nonsteroidal anti-inflammatory drugs. Some anti-inflammatory agents, like pexelizumab, are focused on complement cascade.Another agent is Varespladib, which targets sPLA2 that causes oxidative stress and inflammation. There are other therapeutic targets that have been widely investigated. Colchicine is a substance with potent anti-inflammatory properties, having a unique mechanism of action, which allows for safe use in patients with cardiovascular disease.
Colchicine binds to non-polymerized tubulin, forming a stable complex that effectively inhibits the dynamic of microtubules, depolymerizing them. Thus, any process requiring changes in the cell cytoskeleton, such as cellular mitosis, exocytosis and neutrophil motility, is affected. Colchicine has an important effect on atrial myocytes, changing the atrial response to autonomic effects (reducing the sympathetic activity and increasing the parasympathetic one). Due to this particular mode of action, colchicine has been indicated in atrial fibrillation post-cardiac surgery. A similar trial is being conducted to investigate any effusions or syndromes that occur after myocardial infarction.
The purpose of the present clinical study is to test the hypothesis that a short course of treatment with colchicine could lead to reduced major adverse cardiovascular events (MACE) in acute MI.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 800 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Outcomes of Low-dose Colchicine in Patients With Myocardial Infarction: A Randomized Controlled Trial |
Estimated Study Start Date : | December 2020 |
Estimated Primary Completion Date : | March 2021 |
Estimated Study Completion Date : | June 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Colchicine Group
This group will receive low dose colchicine, 0.5 mg.
|
Drug: Colchicine
The tablet will be given once daily for the span of the study |
Placebo Comparator: Placebo group
This group will receive a placebo drug with a similar shape and mass as that to experimental drug
|
Drug: Placebo oral tablet
The tablet will be given once daily for the span of the study |
- Major cardiovascular adverse events (number of events) [ Time Frame: 3 months ]
This outcome will be assessed using a questionnaire. The following headings will be used:
- Cardiovascular death (number of events)
- Non-fatal myocardial infarction (number of events)
- Resuscitated cardiac arrest (number of events)
- Hospitalization for unstable angina (number of events) For each heading, the total number of events will be recorded and the numbers will all be added to calculate 'Major Adverse Cardiovascular Events' in form of number of events. This outcome has no specific values of measure but a discrete numerical value
- Troponin I (ng/ml) [ Time Frame: 3 months ]This workup will be recorded on the same questionnaire as a numerical value with its specific unit of measure upon followup of patient.
- Creatine Kinase-Myocardial Band (IU/L) [ Time Frame: 3 months ]This workup will be recorded on the same questionnaire as a numerical value with its specific unit of measure upon followup of patient.
- C-reactive protein (mg/L) [ Time Frame: 3 months ]This workup will be recorded on the same questionnaire as a numerical value with its specific unit of measure upon followup of patient.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All patients 18 years or above presenting in emergency department with acute myocardial infarction. These patients will be requested to take the medication at the time of discharge after stabilization and management
Exclusion Criteria:
- Patients with prior myocardial infarction 30 days before
- Patients with ischemic cardiomyopathy
- Age <18 or > 80 years
- Active inflammatory or infectious disease or known malignancy
- Known hypersensitivity to colchicine,
- renal failure (eGFR <30ml.min.1.73m)
- hepatic failure
- Stent thrombosis
- Cardiac arrest or cardiogenic shock as presenting symptoms

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04218786
Pakistan | |
Rawalpindi Institute of Cardiology | |
Rawalpindi, Pakistan, 46000 |
Principal Investigator: | Nismat Javed, MBBS student | Shifa College of Medicine, Shifa Tameer-e-Millat University | |
Study Director: | Jahanzeb Malik, MBBS (2011) | Rawalpindi Institute of Cardiology | |
Study Chair: | Adeel ur Rehman, MBBS, FCPS | Rawalpindi Institute of Cardiology |
Responsible Party: | Nismat Javed, Principal Investigator, Shifa Tameer-e-Millat University |
ClinicalTrials.gov Identifier: | NCT04218786 |
Other Study ID Numbers: |
STMU2020 |
First Posted: | January 6, 2020 Key Record Dates |
Last Update Posted: | November 3, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
colchicine; outcome: myocardial infarction |
Myocardial Infarction Myocardial Ischemia Infarction Ischemia Pathologic Processes Necrosis Heart Diseases Cardiovascular Diseases Vascular Diseases |
Colchicine Gout Suppressants Antirheumatic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |